

17.01.2022

PRESS RELEASE

Generali in Germany invests in research on therapy for post-COVID diseases

- **Through the engagement, a robotic-assisted therapy from Movendo Technology will be implemented to study the medical impact following COVID-19 disease**
- **Patients suffering from post-COVID often present with cardiovascular, pulmonary or psychological problems, as well as neurological disorders that have not yet been fully explored.**
- **Movendo Technology is already working with the Ludwig-Maximilians-University Hospital in Munich (LMU), the Schmieder Clinics in Constance, other clinics as well as therapy and rehabilitation centers**

Pressekontakt

Giulio Benedetti
Leiter Unternehmenskommunikation
und Public Affairs
T +49 (0) 89 5121-8294

Stefan Göbel
Unternehmenskommunikation
Leiter Externe Kommunikation
T +49 (0) 89 5121-6100

Nicole Skalicky
Unternehmenskommunikation
Externe Kommunikation
T +49 (0) 221 1636-2319

presse.de@generali.com

Generali Deutschland AG
Adenauerring 7
D-81737 München

www.generali.de

Twitter: @GeneraliDE

Munich – With its claim to innovation leadership in the insurance industry, Generali supports the development of cutting-edge technologies in Germany and thus promotes the early market launch of pioneering research findings. The most recent project is the "hunova" robot system from the Italian company Movendo Technology. At the LMU Clinic, post-COVID patients are currently undergoing a detailed and extended diagnostic evaluation with a view to neurological consequential diseases. This is supported by the "hunova" robot system, which is also part of the rehabilitation approach.

Giovanni Liverani, CEO of Generali Deutschland AG, explains: *"As a leading company and Lifetime Partner of our customers, we see it as our responsibility to support medical progress and invest in innovative treatments. In particular, the number of post-COVID patients who persistently suffer from the effects of the viral disease will unfortunately continue to rise in the coming months or years. With digital rehabilitation solutions that enable targeted diagnostics and successful therapy, we can help patients regain a higher quality of life faster."*

Simone Ungaro, CEO and founder of Movendo Technology, adds, *"Thanks to Generali's important support, we can now extend our robotic approach to post-COVID patients in Germany - with the aim of reducing or even avoiding possible chronification tendencies of this disease and to better understand the intrinsic causes of the deficits."*

ROBOTIC SYSTEM EVALUATES POST-COVID DEFICITS

The focus is on symptoms that are difficult to quantify with conventional diagnostics, such as persistent exhaustion and fatigue ("fatigue syndrome"),



muscle weakness, as well as limited resilience, cognitive impairment, and dizziness or balance disorders. With the help of the "hunova" robotic system, an objective database is created for the first time and the severity of the neurological disorders is assessed on the basis of comparative data from healthy people – in addition to the deficits affecting the heart and lungs (cardiopulmonary deficits). Through these results, individualized rehabilitation approaches can be developed and applied. The goal is to treat deficits early, in a targeted and personalized manner, so that symptoms do not become permanently entrenched.

According to the World Health Organization, around a quarter of people with COVID-19 still have symptoms four to five weeks after a positive test and around one in ten patients even after twelve weeks. All of this can seriously impair the quality of life and ability to work of those affected.¹

INTENSIVE PARTNERSHIP ALSO IN FALL PREVENTION

Generali in Germany has a lot of experience in developing new healthcare solutions together with scientific institutions and innovative technology companies such as Movendo Technology. Earlier this year, the company announced its cooperation with Movendo in the development of a pioneering robotic fall prevention solution to reduce falls, especially in the 65+ age group.

GENERALI IN GERMANY

Generali is one of the leading primary insurance groups in the German market with premium income of €14.4 billion and around 10 million customers at the end of 2020. As part of the international Generali Group, Generali operates in Germany with the Generali, CosmosDirekt and Dialog brands in the life, health and property/casualty segments. Generali's objective is to be a lifelong partner for its customers, offering innovative, individual solutions and services thanks to an excellent sales network in tied and direct sales as well as in the broker channel.

MOVENDO TECHNOLOGY

Movendo Technology, part of the biopharmaceutical group Dompé Holdings, was founded in 2016 as a spin-off of the Italian Institute of Technology. Headquartered in Genoa (Italy), with offices in Munich (Germany) and Boston (USA), Movendo Technology develops and markets robotic and digital rehabilitation solutions for objective, functional assessments and effective treatments. hunova®, the company's flagship product and one of the most versatile robotic assistive devices on the market, improves neurological, orthopedic and geriatric diagnosis and rehabilitation, and supports active aging and athletic performance. Proprietary software algorithms and novel IT and machine learning solutions provide predictive and personalized therapy, telerehabilitation, and data-driven population health management tools.

The security of your personal information is very important to us. Please let us know if you no longer wish to receive information from us. We will then delete your data from our mailing list.

¹ World Health Organization, Regional Office for Europe, URL: <https://www.euro.who.int/de/health-topics/health-emergencies/coronavirus-covid-19/news/news/2021/2/new-policy-brief-calls-on-decision-makers-to-support-patients-as-1-in-10-report-symptoms-of-long-covid> (Stand: 25.11.2021).